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ABSTRACT
Neuroblastoma is the most common extracranial solid tumor of childhood and 
accounts for 15% of all pediatric cancer-related deaths. New therapies are needed to 
improve outcomes for children with high-risk and relapsed tumors. Inhibitors of the 
RET kinase and the RAS-MAPK pathway have previously been shown to be effective 
against neuroblastoma, suggesting that combined inhibition may have increased 
efficacy. RXDX-105 is a small molecule inhibitor of multiple kinases, including the 
RET and BRAF kinases. We found that treatment of neuroblastoma cells with RXDX-
105 resulted in a significant decrease in cell viability and proliferation in vitro and in 
tumor growth and tumor vascularity in vivo. Treatment with RXDX-105 inhibited RET 
phosphorylation and phosphorylation of the MEK and ERK kinases in neuroblastoma 
cells and xenograft tumors, and RXDX-105 treatment induced both apoptosis and 
cell cycle arrest. RXDX-105 also showed enhanced efficacy in combination with 
13-cis-retinoic acid, which is currently a component of maintenance therapy for 
children with high-risk neuroblastoma. Our results demonstrate that RXDX-105 
shows promise as a novel therapeutic agent for children with high-risk and relapsed 
neuroblastoma.
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INTRODUCTION
Neuroblastoma is the most common extracranial 
solid tumor of childhood and accounts for 15% of all 
pediatric cancer-related deaths [1]. Current treatment for 
children with high-risk neuroblastoma includes intensive 
multimodal therapy with significant associated morbidity 
[2, 3]. Despite initial responses to therapy, children with 
high-risk neuroblastoma tumors suffer from frequent 
relapses, and relapsed tumors are often refractory to 
current treatment. Thus, overall outcomes are poor for this 
patient population, with overall survival rates less than 
20% [4–6]. New therapeutic agents directed against novel 
targets and mechanisms are needed to address the clinical 
needs of these patients.
The REarranged during Transfection (RET) gene 
encodes a receptor tyrosine kinase that is a known 
oncoprotein, with oncogenic mutations identified in 
multiple tumor types. RET is expressed on neural crest-
derived cells and is important for the maturation of 
sympathetic neurons [7]. RET has also been shown to be 
expressed on neuroblastoma tumor cells [8], and transgenic 
mice overexpressing RET develop neuroblastoma tumors 
[9]. RET expression is also associated with increased 
neuroblastoma metastases in vivo [10], and RET expression 
is higher in neuroblastoma tumors from patients with stage 
4 and high-risk disease [11]. These results suggest that 
RET may play an important role in neuroblastoma cell 
survival, proliferation, and metastasis, and therefore RET 
is an appealing target for novel therapeutic agents.
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The RAS-RAF-MAPK pathway is activated 
downstream of RET and other receptor tyrosine kinases 
and is likewise frequently mutated in numerous types of 
human cancer [12]. Single mutations in the RAS-MAPK 
pathway are uncommon in neuroblastoma tumors at 
the time of initial diagnosis, with mutations of BRAF 
seen in approximately 1% of tumors and other RAS-
MAPK pathway mutations only found in approximately 
3–5% [13–14].  Recent investigations, however, 
identified a majority of relapsed neuroblastoma tumors 
with mutations suspected to activate the RAS-MAPK 
pathway [15, 16]. These results suggest that the RAS-
MAPK pathway potentially plays a role in the resistance 
of neuroblastoma tumors to upfront therapy and that 
RAS-MAPK pathway inhibition may be most effective 
in children with relapsed neuroblastoma.
RXDX-105 is a novel, small molecule, multi-
kinase inhibitor with potent activity against wild type 
RET, RET fusions, and RET activating mutations as 
well as other kinases [17] (Figure 1). RXDX-105 is 
orally available and has been tolerated well by adults 
in phase I/Ib clinical trials [18, 19]. Given the evidence 
for the roles of RET and the RAS-MAPK pathway in 
neuroblastoma pathogenesis and treatment resistance, 
we hypothesize that RXDX-105 should have significant 
antitumor effects in in vitro and in vivo models of 
neuroblastoma and may be a promising new therapy for 
children with relapsed neuroblastoma.
RESULTS
RXDX-105 decreases neuroblastoma cell 
viability and proliferation
To determine the effects of RXDX-105 on 
neuroblastoma cell viability, a set of 11 established 
neuroblastoma cell lines, representing a range of biological 
and cytogenetic phenotypes (Supplementary Table 1), 
were cultured in physiologically relevant concentrations 
of RXDX-105 [19]. Cell viability was assessed with 
alamarBlueTM assays performed after 72 hours of 
incubation with the drug. IC50 values were calculated and 
ranged from 3.5 µM and 14.4 µM (Figure 2), suggesting 
that neuroblastoma cells are sensitive to RXDX-105 
at physiologically achievable doses. We also assessed 
the effects of RXDX-105 on cell confluence utilizing 
continuous live cell imaging. Cell confluence in treated 
cells compared to untreated cells was calculated at 72 
hours. IC50 values for confluence were similar to those 
calculated from cell viability assays (Supplementary Table 
2). No apparent associations were observed between known 
cytogenetic and biologic features of the neuroblastoma cell 
lines, including MYCN amplification or other cytogenetic 
abnormalities or p53 mutations, and sensitivity to 
RXDX-105.
RXDX-105 induces neuroblastoma cell apoptosis 
and cell cycle arrest
To assess the mechanisms through which RXDX-
105 inhibited cell viability and reduced confluence, we 
performed assays to measure apoptosis in neuroblastoma 
cells treated with RXDX-105 and equivalent controls. 
RXDX-105 treatment resulted in significantly increased 
caspase and PARP cleavage in all cell lines tested in a dose 
dependent manner (Figure 3), suggesting that RXDX-105 
exposure induces apoptosis in neuroblastoma cells.
To determine the effects of RXDX-105 on cell 
cycle progression, neuroblastoma cells were treated with 
RXDX-105 and analyzed by flow cytometry for DNA 
content. 24 hours of RXDX-105 exposure resulted in a 
significant increase in the percentage of cells in the G0/G1 
phase and a concurrent decrease in the percentage of S/G2 
phase cells (Figure 3), suggesting that both induction of 
apoptosis as well as cell cycle arrest underlie the decreased 
viability and confluence seen in RXDX-105-treated 
neuroblastoma cells.
RXDX-105 inhibits target kinases and 
intracellular signaling pathways
RXDX-105 is a potent inhibitor of multiple 
kinases, including the RET and BRAF kinases 
(Figure 1) [17]. To investigate whether RXDX-105 is 
able to inhibit the RET kinase and the RAS-MAPK 
pathway in neuroblastoma cells, we evaluated a panel 
of neuroblastoma cell lines for RET, MEK, and ERK 
expression and phosphorylation after 24 hours of treatment 
with RXDX-105. RET phosphorylation was inhibited 
with RXDX-105 treatment in a dose dependent manner, 
while levels of total RET remained relatively stable. RET 
phosphorylation was also increased after the addition of 
5 µM 13-cis-retinoic acid, which was also inhibited by 
RXDX-105 (Figure 4). RXDX-105 treatment also resulted 
in significantly decreased MEK and ERK phosphorylation, 
while levels of total ERK remained the same or slightly 
increased (Figure 4, Supplementary Figure 1).
Sensitivity to RXDX-105 is related to RAS-
MAPK pathway gene expression
Cell lines with gene expression data available 
were analyzed to assess for differences in the expression 
of genes for intracellular signaling pathway proteins 
that might explain the differences seen in sensitivity to 
RXDX-105. The median IC50 for all cells tested was 8.0 
µM. Cells with IC50s less than 8.0 µM, including Kelly, 
SK-N-AS, and SK-N-BE (2), trended toward having 
increased expression of RAS-MAPK pathway genes 
(Supplementary Figure 2), while there was no appreciable 
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trend between RET gene expression and RXDX-105 
sensitivity (data not shown).
RXDX-105 demonstrates enhanced efficacy 
when combined with 13-cis-retinoic acid
We have previously demonstrated synergistic 
efficacy of the combinations of RET inhibitors with 
13-cis-retinoic acid, a vitamin A analog currently used 
as maintenance therapy in children with high-risk 
neuroblastoma [20, 21]. To determine the efficacy of the 
combination of RXDX-105 and 13-cis-retinoic acid, we 
plated cells with and without 5 µM 13-cis-retinoic acid 
with increasing doses of RXDX-105 for 72 hours before 
performing alamarBlueTM assays. 13-cis-retinoic acid had 
no significant effect on cell viability as a single agent, 
but the combination of RXDX-105 with 13-cis-retinoic 
acid resulted in a significant decrease in cell viability in 
all cells tested, compared to RXDX-105 alone (Figure 5; 
Supplementary Figure 3).
RXDX-105 inhibits neuroblastoma xenograft 
tumor growth
To evaluate the efficacy of RXDX-105 against 
neuroblastoma tumors in vivo, we utilized an orthotopic 
xenograft model, injecting neuroblastoma cells into the 
exposed left adrenal glands of immunocompromised mice 
(Figure 6) [21]. RXDX-105 was well tolerated without 
any decrease in mouse weight or other appreciable side 
effects (Supplementary Figure 4). Treatment with RXDX-
105 resulted in significant reduction in final tumor weights 
in both SK-N-AS (4.7 g ± 2.5 g vs. 0.85 g ± 0.65 g, 
p = 0.0001) and SK-N-SH (2.3g ± 1.4 g vs. 0.43 g ± 0.37 g, 
p = 0.002) xenograft tumors after 4 and 6 weeks of treatment 
respectively (Figure 6, Supplementary Figure 5).
RXDX-105 inhibits RET phosphorylation and 
intracellular signaling downstream of BRAF in 
orthotopic neuroblastoma tumors
To determine whether RXDX-105 treatment was 
also able to inhibit RET phosphorylation as well as 
the RAS-MAPK pathway in mice with neuroblastoma 
xenograft tumors, we evaluated lysates of harvested 
tumors by Western blots for total and phosphorylated 
RET, MEK, and ERK. Neuroblastoma tumors from 
mice treated with RXDX-105 demonstrated decreased 
levels of phosphorylated RET as well as decreased 
phosphorylation of MEK and ERK (Figure 6), suggesting 
that the mechanism of efficacy of RXDX-105 in vivo is 
likely similar to its mechanism in vitro.
Figure 1: (A) The RET, RAS-RAF-MAPK pathway with sites of RXDX-105 inhibition in red. (B) RXDX-105 (CEP-32496) structure. 
(C) RXDX-105 inhibition of potential target kinases (adapted from [17]).
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RXDX-105 treatment leads to decreased 
angiogenesis in vivo
We noted a significant difference in the gross 
appearance of RXDX-105-treated and vehicle control-
treated tumors in orthotopic neuroblastoma tumor models, 
with the RXDX-105-treated tumors being notably paler 
in appearance and less friable and hemorrhagic on 
gross appearance (Figure 6). To evaluate the effects of 
RXDX-105 on neuroblastoma tumor vascularity, tumor 
samples were immunostained for vascular endothelial 
cells with anti-CD31 antibodies and mean vessel density 
was calculated in treated and untreated tumors. Mean 
vessel density was significantly decreased in tumors 
from mice treated with RXDX-105 compared to control 
tumors, suggesting the efficacy of RXDX-105 against 
neuroblastoma tumors is mediated in part by a potent anti-
angiogenic effect (Figure 7).
Figure 2: RXDX-105 decreases neuroblastoma cell viability and proliferation. Cell viability was assessed with alamarBlueTM 
assays performed after 72 hours of incubation with RXDX-105, and dose-response curves (left) and calculated IC50 values (right) are 
shown.  
Figure 3: RXDX-105 induces neuroblastoma cell apoptosis and cell cycle arrest. (A) Neuroblastoma cells were plated and 
treated with vehicle control or decreasing doses of RXDX-105 with additional caspase 3/7 reagent. Cells were monitored with continuous 
live cell imaging and total caspase cleavage was determined by counting sites of activated caspases (in green) at 72 hours. (B) Cell lysates 
were assessed for PARP cleavage by Western blot after 24 hours of RXDX-105 treatment. (C) The effect of RXDX-105 treatment on cell 
cycle was assessed using flow cytometry for DNA content after 24 hours of treatment.
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DISCUSSION
New therapies are needed for children with high-
risk and relapsed neuroblastoma who continue to have 
poor outcomes despite intensive treatment. We have 
demonstrated that the novel kinase inhibitor RXDX-105 
is effective against neuroblastoma in both in vitro and in 
vivo models.
RET has been previously shown to be highly 
expressed in neuroblastoma cells, and constitutively 
activated RET enhances neuroblastoma metastases in vivo 
[8, 10]. A recently described subset of approximately 10% 
Figure 4: RXDX-105 inhibits target kinases and intracellular signaling pathways. Neuroblastoma cell lines were treated 
with either vehicle or decreasing doses of RXDX-105 for 24 hours in combination with 5 μM 13-cis-retinoic acid to stimulate RET 
phosphorylation. Cells were lysed and Western blots were performed to assess RET and ERK expression and phosphorylation. GAPDH 
expression is shown as a loading control. 
Figure 5: RXDX-105 efficacy is enhanced when combined with 13-cis-retinoic acid. SK-N-BE(2) neuroblastoma cells were 
treated with decreasing doses of RXDX-105 alone or in combination with 5 µM 13-cis-retinoic acid for 72 hours and cell viability was 
assessed with an alamarBlue™ assay.  Cell viability at each dose of RXDX-105 is shown.
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of primary neuroblastoma tumors with ALK mutations 
has been shown to be driven through RET upregulation 
[22]. Our results add further evidence that RET plays a 
significant role in neuroblastoma cell proliferation and 
survival and that the RET kinase represents a promising 
therapeutic target. Prior studies of RET inhibitors have 
also demonstrated efficacy against neuroblastoma in vitro 
and in vivo through decreasing neuroblastoma viability 
and induction of apoptosis [11, 20, 21]. However, these 
inhibitors, like RXDX-105, also inhibit other important 
targets in critical signaling pathways which likely 
contribute significantly to their antitumor effects. The 
Figure 6: RXDX-105 inhibits tumor xenograft growth and inhibits RET phosphorylation and intracellular signaling 
in orthotopic neuroblastoma tumors. (A) SK-N-AS and SK-N-SH cells were injected into the left adrenal glands of nude mice as 
shown. Mice were then randomized and treated once daily orally with vehicle control or RXDX-105. SK-N-AS tumors were harvested at 
4 weeks and SK-N-SH tumors at 6 weeks, based on tumor growth rates. (B) Final tumor weight was measured in harvested tumors and 
weights of tumors from treated mice were compared to weights of tumors from control mice. (C) Images and measurements from harvested 
tumors are shown, with untreated tumors in the top rows and treated tumors in the bottom rows.  (D) Tumor cell lysates were analyzed by 
Western blot for expression and phosphorylation of RET, MEK and ERK in tumors from treated and control mice. 
Figure 7: RXDX-105 treatment leads to decreased angiogenesis in vivo. (A) Drug treated tumor samples were noted to be less 
vascular and hemorrhagic on gross appearance and H&E staining. (B) Tumor samples were immunostained for vascular endothelial cells 
with anti-CD31 antibodies and photographed at 10× magnification.  (C)  Mean vessel density was calculated using the number of observed 
vessels per high power field and compared in both treated and untreated tumors. 
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effects of RXDX-105 in neuroblastoma are potentially due 
to the combination of the effects of inhibition of multiple 
kinases, including RET, BRAF, Abl, and EphA2 (Figure 1), 
and further studies are needed to clarify the relative roles of 
these disparate kinases in the responses of neuroblastoma 
cells to RXDX-105.
Prior studies have also demonstrated the efficacy 
of MEK inhibitors against neuroblastoma models 
[15, 23, 24]. Our results demonstrate that RXDX-105 
inhibits both RET and the RAS-MAPK pathway, which 
likely both contribute to the observed potent in vitro 
and in vivo antitumor effects and suggest that RET and 
its downstream RAS-MAPK pathway are involved in 
neuroblastoma pathogenesis. Our results are further 
supported by the trend seen towards increased cell line 
sensitivity to RXDX-105 in cell lines with increased 
RAS-MAPK pathway gene expression, and there was 
no observed relationship between MYCN amplification 
or other cytogenetic abnormalities or p53 mutations with 
responses to RXDX-105.
Our results have also shown that RXDX-105 
treatment of neuroblastoma tumors results in a decrease in 
tumor vascularity. Prior studies have shown that treatment 
of neuroblastoma tumors with vandetanib, a RET, VEGFR, 
and EGFR inhibitor, resulted in a significant decrease 
in tumor angiogenesis in vivo [20]. RXDX-105 has 
previously been shown to have minimal inhibitory effect 
on VEGFR, potentially minimizing some of the known 
dose-limiting side effects of previously studied VEGFR 
inhibitors, such as hypertension [17]. It has previously 
been suggested that RET stimulation may promote 
angiogenesis through the activation of pro-inflammatory 
mediators and the recruitment of primary immune cells 
to the tumor microenvironment, which subsequently 
promotes angiogenesis and suggests that RET inhibition 
inhibits angiogenesis by blocking this activation [26]. Our 
results demonstrating an antiangiogenic effect of RXDX-
105 in immunocompromised mouse models, however, 
suggest that RET, and possibly the RAS-MAPK pathway, 
may play previously undescribed roles in neuroblastoma 
tumor angiogenesis, although direct antiangiogenic effects 
of EphA2 inhibition, in addition to inhibition of VEGFR1 
and VEGFR2, also cannot be completely ruled out at the 
concentrations likely achieved in our mice treated with 
RXDX-105.
Our results also demonstrate that the combination 
of RXDX-105 and 13-cis-retinoic acid is more effective 
than either agent alone. 13-cis-retinoic acid is a Vitamin A 
analog currently used for maintenance therapy in treatment 
regimens for children with high-risk neuroblastoma 
[3], and 13-cis-retinoic acid has been shown to induce 
neuroblastoma tumor differentiation, decrease MYCN 
expression, and decrease neuroblastoma cell proliferation 
[27–30]. 13-cis-retinoic acid treatment has been shown 
to induce dependence on neurotrophin and glial-derived 
neurotrophic factor signaling through the RET kinase 
[31, 32], suggesting that the observed synergistic effects of 
RET inhibition with 13-cis-retinoic acid are possibly due 
to the induction of oncogenic addiction to RET signaling 
[33, 34], which subsequently sensitizes neuroblastoma 
cells to RET inhibition.
In summary, we have demonstrated that the novel 
multikinase inhibitor RXDX-105 is effective against 
neuroblastoma tumors both in vitro and in vivo. RXDX-
105 treatment of neuroblastoma cells and xenograft tumors 
results in inhibition of RET and the RAS-MAPK pathway, 
adding further evidence to the critical roles these proteins 
and pathways play in neuroblastoma tumorigenesis. 
Given this demonstrated efficacy, further preclinical and 
clinical testing of RXDX-105 in patients with relapsed 
neuroblastoma is warranted.
MATERIALS AND METHODS
Cells and culture conditions
The neuroblastoma cell lines SK-N-AS, SK-N-SH, 
IMR-32, SK-N-BE (2), LA-N-1, LA-N-5, LA1-55N, 
Kelly, NGP, CHP-134, and SJ-NB-10 have been previously 
described [20, 21, 24]. Cell lines were maintained in 
RPMI-1640 (Mediatech Inc, Manassas, VA, USA) with 
10% fetal bovine serum (Omega, Tarzana, CA, USA), 
L-glutamine, non-essential amino acids (Mediatech Inc), 
sodium pyruvate (Mediatech Inc), and Hyclone antibiotic/
antimycotic (Fisher Scientific, Hampton, NH, USA) at 
37°C in 5% CO2.
RXDX-105
RXDX-105 was generously provided by Ignyta, 
Inc. (San Diego, CA, USA). In vitro experiments were 
performed with RXDX-105 (free base), which was 
dissolved in dimethylsulfoxide (DMSO) to create a 25 mM 
stock solution, which was maintained at 4° C for 1 week 
at a time and protected from light. In vivo experiments 
were performed with RXDX-105 (HCl salt), which was 
dissolved in 22% (2-Hydroxypropyl)-β-cyclodextrin 
(HPBCD; Sigma Aldrich, St. Louis, MO, USA) stored at 
4°C for 1 week at a time.
Cell confluence assay
Cells were plated in 96-well plates at seeding 
densities between 5,000–10,000 cells/well for 24 hours. 
Cells were then treated with varying concentrations of 
RXDX-105 or equivalent doses of DMSO for control. 
Plates were placed in the Incucyte ZoomTM continuous 
live cell imaging system (Essen Bioscience, Ann Arbor, 
MI, USA) and phase contrast images were taken every 6 
hours at 10× magnification for up to 96 hours. Cell growth 
curves were generated from percent cell confluence 
acquired from the Incucyte ZoomTM analyzer. Replicates of 
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at least three wells were used for each drug concentration 
for every experiment and each experiment was repeated at 
least three independent times. IC50 values were derived 
using best-fit trend lines and the values were calculated 
using the appropriate curve-fit equations.
CASPASE 3/7 apoptosis assay
Cells were plated in 96-well plates at seeding 
densities of 5,000 cells/well and treated with RXDX-
105 at different concentrations as above. Caspase 3/7 
Reagent (Essen Bioscience) was added 24 hours after 
plating. Plates were placed in the Incucyte Zoom™ live 
cell imaging system and phase contrast images as well 
as green fluorescent images were taken every 6 hours 
at 10× magnification for 72 hours. Fold apoptosis was 
generated from green signal counts measured by the 
Incucyte Zoom™ analyzer for treated cells and normalized 
to the green signal count measured for control wells. 
Replicates of at least three wells were used for each drug 
concentration for every experiment.
Cell viability assay
Cells were plated in 96-well plates at a seeding 
density of 5,000 cells/well and incubated overnight. Cells 
were then treated with varying concentrations of RXDX-
105 or equivalent doses of DMSO for control. After 72 
hours of incubation with RXDX-105, alamarBlue™ Cell 
Viability Reagent (Invitrogen, Carlsbad, CA, USA) was 
added at 10% of total volume. Cells were then incubated 
from 1–6 hours at 37° C protected from light. Plates were 
read on Tecan i200 spectrophotometer at 590 nm. Viability 
as determined by signal intensity was normalized to control 
wells.
Combinations with 13-cis-retinoic acid
SK-N-BE (2) neuroblastoma cells were plated in 
96 well plates at approximately 50% confluence, given 
24 hours to adhere, and then were treated with either 
escalating concentrations of RXDX-105 alone or in 
combination with 5 µM 13-cis-retinoic acid. SK-N-BE (2), 
SK-N-SH, SK-N-AS, and Kelly neuroblastoma cells were 
plated as above and treated with 5 µM 13-cis-retinoic acid, 
1 µM of RXDX-105, or the combination of 5 µM 13-cis-
retinoic acid and 1 µM of RXDX-105. Cells were treated 
for 72 hours and viability was assessed in each case using 
alamarBlue™ assays. Percent viability was obtained by 
normalizing each cell line and treatment to its respective 
vehicle control.
Cell cycle analysis
Cell were treated for 24 hours with decreasing 
concentrations of RXDX-105 or equivalent concentrations 
of vehicle alone. Cells were then harvested and fixed in 
cold 70% ethanol and stored for at least 24 hours at −20° C. 
Prior to flow cytometry, cells were resuspended and 
rehydrated in PBS, treated with 100 μg/ml RNAse and then 
stained with 50 μg/ml propidium iodide. Samples were 
run on FACSCanto-II flow cytometer (BD Biosciences, 
Franklin Lakes, NJ, USA). Data was analyzed using 
FlowJo Software (TreeStar Inc., Ashland, OR, USA).
Gene expression analysis
Using neuroblastoma cell line gene expression 
data [25] we performed oncoGPS analysis as previously 
described [35] on the Kelly, IMR-32, SK-N-AS, SK-
N-BE (2), LA-N-5, SK-N-SH, CHP-134, and NGP 
neuroblastoma cell lines. Gene expression levels in the 
RAS signal transduction, BIOCARTA MAPK, positive 
regulation of MAPK Cascade, and KEGG MAPK 
signaling pathway gene sets from the Molecular Signatures 
Database [36] were evaluated in these 8 cell lines.
Western blotting
Cells were plated in 6-well plates at approximately 
70–80% confluence and allowed to adhere overnight. 
Wells were treated with RXDX-105 at different 
concentrations for 24 hours. RET phosphorylation was 
stimulated with 5 µM 13-cis-retinoic acid. Cells were 
then washed with PBS and lysed with RIPA buffer 
supplemented with Protease inhibitor and phosphatase 
inhibitor (Life Technologies, Carlsbad, CA, USA). Lysates 
were centrifuged and the supernatants were collected.
Xenograft tumors were snap frozen in liquid nitrogen 
at time of harvest (see below). Frozen tumor samples 
were broken up using a BioPulverizer (Biospec Products, 
Bartlesville, OK, USA) and lysed with RIPA buffer with 
1% SDS, 10% protease inhibitor, and 10% phosphatase 
inhibitor.
Protein concentration in cell and tumor lysates was 
measured using a protein assay Dye Reagent (Bio-Rad, 
Hercules, CA, USA). 20–30 μg of denatured total protein 
from each sample was separated by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
using 4–12% Bolt gels (Invitrogen, Carlsbad, CA, USA) 
and transferred to PVDF membranes. Membranes were 
blocked with 3% BSA made in 1× TBS + 0.1% Tween 
20 and then incubated with primary antibodies to total 
RET (#3220S), phospho-RET (#32212), total MEK1/2 
(#9126S), phospho-MEK (#9154S), total ERK (#4695S), 
phospho-ERK (#4370S), PARP (#9542S), and GAPDH 
(#5174S) (all antibodies obtained from Cell Signaling 
Technology, Danvers, MA, USA). All antibodies were 
diluted in 5% BSA in 1× TBS + 0.01% Tween-20. Bound 
primary antibodies were incubated in anti-rabbit or anti-
mouse HRP-conjugated secondary antibodies (1:5000, 
Sigma-Aldrich) at room temperature for 1 hour and 
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the signal was visualized using Amersham ECL (GE 
Healthcare Bio-Sciences, Pittsburgh, PA, USA).
Mouse tumor models
All mouse protocols were approved by the 
University of California, San Diego Institutional Animal 
Care and Use Committee (IACUC). Eight-week-old 
female athymic (nu/nu) mice were obtained from the 
UCSD Moores Cancer Center. Mice were anesthetized 
with the combination of ketamine and buprenorphine. 
1 × 106 luciferase-labelled SK-N-SH and SK-N-AS cells 
in 4 µL of PBS were injected into the exposed left adrenal 
glands of sedated mice. IVIS imaging was performed 
every 4 days, and once tumor signal was identified, mice 
were randomized and treated with either 80 mg/kg/day of 
RXDX-105 or equivalent volume of 22% HPBCD vehicle 
control by oral gavage. Animals were treated until tumors 
reached institutional limits, at which point all of the mice 
in the cohort were sacrificed and tumors were harvested. 
Tumor samples were divided, with half snap frozen in liquid 
nitrogen (see above) and half fixed in formalin (see below).
Immunohistochemistry
Tumor samples were fixed in 1% Zn-Formalin 
for 24 hours then placed in 70% ethanol. Serial sections 
were used for immunohistochemistry. To assess vascular 
endothelial cells, frozen sections were incubated with 
rabbit anti-CD31 primary antibody (Abcam, Cambridge, 
UK; ab28364, 1:50) followed by anti-rabbit HRP-
conjugated secondary antibody (Biocare, Pacheco, CA, 
USA; RMR 622). Sections were then stained with DAB 
(brown) chromogen (Biocare; IPK5010 G80) and Mayer’s 
hematoxylin (Sigma-Aldrich) counterstain and mounted 
with xylene based mountant. For calculation of mean 
vessel density, stained sections were assessed under light 
microscopy. Ten high-power field images (20×) were 
taken per section and the number of discrete vessels were 
counted per image in blinded fashion. Results are reported 
as average number of vessels per high power field.
Statistical analysis
Experiments were performed at least in triplicate. 
Two tailed Student t tests were used to compare 
significance between means for in vitro and in vivo 
experiments.
Abbreviations
ERK: extracellular signal-related kinase; FBS: 
fetal bovine serum; GDNF: glial derived neurotrophic 
factor; MAPK: mitogen-activated protein kinase; MEK: 
MAPK/ERK kinase; PARP: poly ADP ribose polymerase; 
PBS: phosphate-buffered saline; PI: propidium iodide; 
RET: REarranged during Transfection; RTK: receptor 
tyrosine kinases; SDS: sodium dodecyl sulfate; SDS-
PAGE: sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis; VEGFR: vascular endothelial growth 
factor receptor.
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